Gold prices fell below a critical support level as persistent inflation and Federal Reserve tightening pressured the market, despite a recent drop in U.S. 10-year Treasury yields. The decline was intensified by technical selling and liquidity concerns, with gold experiencing its worst weekly selloff since June. Analysts suggest the selloff reflects short-term market dynamics rather than a fundamental shift, noting potential for a rebound if technical conditions improve. Upcoming central bank meetings, including the Federal Reserve's, will be closely watched for signals on interest rates and inflation, which will influence gold's near-term outlook.
Gold's recent price drop below $4,000 contrasts with the broader US stock market performance on Pluang as of Oct 24, 2026 02:51 WIB: out of 150 US stocks, 43 rose while 106 fell. Among notable movers, United Airlines Holdings Inc (UAL) declined 3.93% to USD 97.99 with 100% buy orders and a typical hold time of 46 days, while Accenture plc (ACN) fell 3.85% to USD 248.79 with predominantly sell orders (99%) and a longer hold time of 130 days. American Express Co (AXP) dropped 3.65% to USD 313.12 with a balanced order activity and a hold time of 124 days, reflecting varied investor behavior across these assets.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
